Simplex Trading, LLC Tg Therapeutics, Inc. Transaction History

Simplex Trading, LLC

  • $3.28 Billion
  • Q4 2024

A detailed history of Simplex Trading, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 180,098 shares of TGTX stock, worth $5.56 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
180,098
Previous 31,759 467.08%
Holding current value
$5.56 Million
Previous $742,000 630.46%
% of portfolio
0.17%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$21.31 - $35.09 $3.16 Million - $5.21 Million
148,339 Added 467.08%
180,098 $5.42 Million
Q3 2024

Nov 08, 2024
SELL
$17.21 - $25.28 $2 Million - $2.94 Million
-116,349 Reduced 78.56%
31,759 $742,000
Q2 2024

Jul 25, 2024
SELL
$13.32 - $19.19 $555,990 - $801,009
-41,741 Reduced 21.99%
148,108 $2.63 Million
Q1 2024

Apr 25, 2024
SELL
$13.02 - $21.3 $362,893 - $593,673
-27,872 Reduced 12.8%
189,849 $2.89 Million
Q4 2023

Feb 02, 2024
BUY
$6.68 - $18.81 $1.16 Million - $3.27 Million
173,656 Added 394.09%
217,721 $3.72 Million
Q3 2023

Nov 01, 2023
BUY
$8.36 - $26.5 $298,284 - $945,520
35,680 Added 425.52%
44,065 $368,000
Q2 2023

Aug 04, 2023
SELL
$15.48 - $35.0 $964,171 - $2.18 Million
-62,285 Reduced 88.13%
8,385 $208,000
Q1 2023

Apr 27, 2023
SELL
$10.23 - $19.34 $2.1 Million - $3.97 Million
-205,114 Reduced 74.37%
70,670 $1.06 Million
Q4 2022

Feb 02, 2023
BUY
$5.01 - $11.83 $745,267 - $1.76 Million
148,756 Added 117.1%
275,784 $3.26 Million
Q3 2022

Nov 04, 2022
SELL
$4.57 - $8.4 $152,551 - $280,400
-33,381 Reduced 20.81%
127,028 $752,000
Q2 2022

Aug 03, 2022
SELL
$3.74 - $10.66 $9,312 - $26,543
-2,490 Reduced 1.53%
160,409 $681,000
Q1 2022

May 02, 2022
BUY
$7.81 - $20.45 $385,040 - $1.01 Million
49,301 Added 43.4%
162,899 $1.55 Million
Q4 2021

Feb 23, 2022
BUY
$15.2 - $35.51 $1.21 Million - $2.83 Million
79,651 Added 234.63%
113,598 $2.16 Million
Q3 2021

Oct 28, 2021
SELL
$21.78 - $40.45 $65,340 - $121,350
-3,000 Reduced 8.12%
33,947 $1.37 Million
Q2 2021

Aug 12, 2021
BUY
$32.5 - $48.96 $934,147 - $1.41 Million
28,743 Added 350.35%
36,947 $1.43 Million
Q1 2021

Apr 26, 2021
SELL
$41.61 - $54.3 $36,283 - $47,349
-872 Reduced 9.61%
8,204 $0
Q4 2020

Feb 02, 2021
SELL
$25.27 - $54.9 $953,816 - $2.07 Million
-37,745 Reduced 80.62%
9,076 $472,000
Q3 2020

Oct 14, 2020
BUY
$18.49 - $27.24 $456,462 - $672,473
24,687 Added 111.53%
46,821 $1.25 Million
Q2 2020

Jul 13, 2020
BUY
$8.9 - $21.84 $141,305 - $346,753
15,877 Added 253.75%
22,134 $431,000
Q1 2020

Apr 29, 2020
SELL
$7.14 - $15.99 $405,851 - $908,903
-56,842 Reduced 90.08%
6,257 $61,000
Q4 2019

Feb 05, 2020
BUY
$5.1 - $11.2 $186,690 - $409,987
36,606 Added 138.17%
63,099 $700,000
Q3 2019

Oct 15, 2019
BUY
$5.38 - $8.99 $142,532 - $238,172
26,493 New
26,493 $148,000
Q2 2019

Jul 26, 2019
SELL
$6.27 - $8.65 $163,935 - $226,162
-26,146 Closed
0 $0
Q1 2019

Apr 18, 2019
SELL
$4.02 - $8.04 $46,278 - $92,556
-11,512 Reduced 30.57%
26,146 $0
Q4 2018

Jan 16, 2019
BUY
$3.44 - $5.76 $129,543 - $216,910
37,658 New
37,658 $154,000
Q3 2018

Oct 23, 2018
SELL
$5.15 - $14.0 $293,642 - $798,252
-57,018 Closed
0 $0
Q2 2018

Jul 30, 2018
BUY
$12.5 - $15.0 $712,725 - $855,270
57,018 New
57,018 $749,000
Q1 2018

Apr 26, 2018
SELL
$8.7 - $16.8 $394,527 - $761,846
-45,348 Closed
0 $0
Q4 2017

Jan 10, 2018
SELL
$7.35 - $12.3 $73,154 - $122,421
-9,953 Reduced 18.0%
45,348 $371,000
Q3 2017

Oct 25, 2017
BUY
$10.0 - $12.7 $553,010 - $702,322
55,301
55,301 $655,000

Others Institutions Holding TGTX

# of Institutions
371
Shares Held
85.5M
Call Options Held
3.78M
Put Options Held
3M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.49B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email